Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.80 |
| ▸ | PTPRC | P08575 | 3/20 | 0.80 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.80 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903376 | 0.90 | PTPN1 (0.65) | PTPN1PTPRCPTPN2RAB9ANPC1 | |
| SCHEMBL3906183 | 0.89 | PTPN1 (0.77) | PTPN1PTPRCPTPN2 | |
| SCHEMBL3909577 | 0.89 | PTPN1 (0.80) | PTPN1PTPRCPTPN2RAB9ANPC1 | |
| SCHEMBL3908592 | 0.89 | PTPN1 (1.00) | PTPN1PTPRCPTPN2 | |
| SCHEMBL3909541 | 0.85 | PTPN1 (0.77) | PTPN1PTPRCPTPN2 | |
| SCHEMBL3907446 | 0.83 | PTPN1 (0.75) | PTPN1PTPRCPTPN2 | |
| SCHEMBL3916555 | 0.81 | PTPN1 (0.62) | PTPN1PTPRCPTPN2RAB9ANPC1 | |
| SCHEMBL3904866 | 0.81 | PTPN1 (0.59) | PTPN1PTPRCPTPN2 | |
| SCHEMBL3910345 | 0.81 | PTPN1 (0.62) | PTPN1PTPRCPTPN2RAB9ANPC1 | |
| SCHEMBL3914373 | 0.80 | PTPN1 (0.59) | PTPN1PTPRCPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081954-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRO, PTPRS, PTPRM | PTPN1 11/4885PTPRC 5/4885PTPN2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.